Author

Piro Lito

Memorial Sloan Kettering Cancer CenterORCID 0000-0003-2196-3503Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Aaliyah Washington· 1 shared Alberto VidesiD· 1 shared Alexander I. SpiraiD· 1 shared Antonio Cuevas-NavarroiD· 1 shared Aparna HegdeiD· 1 shared Aria VaishnaviiD· 1 shared Arvin C. DariD· 1 shared Ben SangiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaliyah Washington

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 4, 2025

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

Mélanie A. Dacheux, Mengting Wu, Michael T. Scherzer…·Aria Vaishnavi

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

DOI 10.1101/2025.05.04.652129

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 24, 2025

Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Ben Sang, Ling Feng Ye, Feng Hu…·Piro Lito

This study identifies mechanisms of resistance to tri-complex RAS inhibitors in patients with RAS-driven cancers, showing that resistance alterations disrupt the RAS:drug:CYPA tri-complex formation.

12 citations

humanDNA methylation

𝕏 PostBluesky